---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210351"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:00:14.717978+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7

## Summary
- Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.
- Cash, equivalents and marketable securities at $596.8M; expects to fund operations beyond expected launch.
- FDA accepted atacicept BLA for priority review with PDUFA date of July 7, 2026 for IgAN.
- Matt Skelton promoted to CCO; Jane Wright-Mitchell appointed Chief Legal Officer; Christopher Hite added to board.
- Initial Phase 2 PIONEER basket trial results expected Q2 2026; pivotal eGFR data from ORIGIN 3 expected Q1 2027.

## SEC filing metadata
- accession: 0001193125-26-210351
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/0001193125-26-210351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210351
- JSON: https://secwatch.observer/filing/0001193125-26-210351.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210351.txt

## Source-grounded claims
- claim_id: f72a3f1e49423d3e7964809e7c3903ec37ae9010
  claim: Vera Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income a net loss of $121.0 million, EPS a net loss per diluted share of $1.69.
  evidence_excerpt: For the quarter ended March 31, 2026, Vera Therapeutics reported a net loss of $121.0 million, or a net loss per diluted share of $1.69
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/0001193125-26-210351-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.